Alerts will be sent to your verified email
Verify EmailJBCHEPHARM
JB Chem & Pharma
|
Ipca Laboratories
|
Alembic Pharma
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
Number of ANDA's Filed in USA
|
19.0 . | 44.0 . | 257.0 . |
Number of ANDA's Approved By USFDA
|
17.0 . | 18.0 . | 196.0 . |
Domestic Sales Growth - YoY
|
9.4 % | 2.6 % | n/a |
R&D as a % of Total Sales
|
1.55 % | 2.71 % | 7.0 % |
Financials
|
|||
5 yr Average ROE
|
18.27 % | 15.9 % | 17.53 % |
5yr average Equity Multiplier
|
1.5 | 1.41 | 1.58 |
5yr Average Asset Turnover Ratio
|
0.79 | 0.81 | 0.79 |
5yr Avg Net Profit Margin
|
15.59 % | 13.8 % | 14.0 % |
Price to Book
|
10.79 | 5.51 | 4.51 |
P/E
|
57.02 | 60.07 | 34.18 |
5yr Avg Cash Conversion Cycle
|
37.72 Days | 74.74 Days | 11.4 Days |
Inventory Days
|
52.43 Days | 100.02 Days | 92.17 Days |
Days Receivable
|
63.16 Days | 55.52 Days | 59.84 Days |
Days Payable
|
81.2 Days | 120.62 Days | 198.11 Days |
5yr Average Interest Coverage Ratio
|
74.05 | 59.4 | 42.05 |
5yr Avg ROCE
|
22.31 % | 18.97 % | 19.16 % |
5yr Avg Operating Profit Margin
|
24.93 % | 22.38 % | 21.64 % |
5 yr average Debt to Equity
|
0.06 | 0.14 | 0.27 |
5yr CAGR Net Profit
|
16.2 % | 1.13 % | -10.16 % |
5yr Average Return on Assets
|
12.35 % | 11.44 % | 10.9 % |
Shareholdings
|
|||
Promoter Holding
|
53.78 % | 46.3 % | 69.61 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
-2.13 % | 0.01 % | 0.13 % |
Change in Mutual Fund Holding (3 Yrs)
|
4.89 % | 7.98 % | 3.48 % |
JB Chem & Pharma
|
Ipca Laboratories
|
Alembic Pharma
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Customer Wise Break-Up
|
Customer Wise Break-Up
|
-
|
-
|
Asset Break-Up - Segment Wise
|
Asset Break-Up - Segment Wise
|
-
|
-
|